TABLE 3.
Clinical characteristics and symptoms, stratified by willingness to participate in trial for disease-modifying therapy
| Characteristics | Not willing to participate (n = 191) | Willing to participate (n = 354) | p |
|---|---|---|---|
| Age | — | — | 0.670 |
| 18–25 y | 25 (13.1) | 40 (11.3) | — |
| 26–39 y | 62 (32.5) | 109 (30.8) | — |
| 40–59 y | 65 (34.0) | 139 (39.3) | — |
| 60 and older | 39 (20.4) | 66 (18.6) | — |
| Male gender | 82 (42.9) | 157 (44.6) | 0.750 |
| White, non-Latino | 175 (95.6) | 330 (94.8) | 0.495 |
| Autoimmune hepatitis overlap | 16 (8.4) | 33 (9.3) | 0.713 |
| Inflammatory bowel disease | 147 (77.0) | 242 (68.4) | 0.034 |
| Cirrhosis | 18 (9.4) | 44 (12.4) | 0.292 |
| History of receiving ERCP | 103 (53.9) | 178 (50.3) | 0.417 |
| History of antibiotics treatment for cholangitis | 55 (28.8) | 125 (35.3) | 0.123 |
| Current PSC-related therapies | |||
| Ursodiol | 96 (50.3) | 203 (57.3) | 0.113 |
| Chronic antibiotics | 6 (3.1) | 22 (6.2) | 0.121 |
| Vancomycin | 19 (9.9) | 25 (7.1) | 0.238 |
| Pruritus medications | 30 (15.7) | 78 (22.0) | 0.077 |
| Number of symptoms experienced | 4 (1–9) | 5 (2–8) | 0.452 |
| Symptoms | |||
| Fatigue | 129 (67.5) | 242 (68.4) | 0.844 |
| Insomnia | 105 (55.0) | 176 (49.7) | 0.241 |
| Anxiety | 92 (48.2) | 157 (44.4) | 0.393 |
| Joint pain | 73 (38.2) | 145 (41.0) | 0.533 |
| Depression | 79 (41.4) | 140 (39.5) | 0.680 |
| Weakness | 64 (33.5) | 134 (37.9) | 0.314 |
| Abdominal pain | 69 (36.1) | 127 (35.9) | 0.954 |
| Pruritus | 64 (33.5) | 149 (42.1) | 0.050 |
| Liver pain | 65 (34.0) | 132 (37.3) | 0.450 |
| Brain fog | 61 (31.9) | 131 (37.0) | 0.237 |
| Other pain | 49 (25.7) | 98 (27.7) | 0.611 |
| Nausea/vomiting | 55 (28.8) | 94 (26.6) | 0.575 |
| Anorexia | 51 (26.7) | 98 (27.7) | 0.806 |
| Night sweats | 59 (30.9) | 87 (24.6) | 0.112 |
| Jaundice | 31 (16.2) | 27 (7.6) | 0.002 |
Note: Data are n (%).
Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; PSC, primary sclerosing cholangitis.